tradingkey.logo

OraSure Technologies Inc

OSUR

3.120USD

+0.110+3.65%
Cierre 08/04, 16:00ETCotizaciones retrasadas 15 min
234.36MCap. mercado
PérdidaP/E TTM

OraSure Technologies Inc

3.120

+0.110+3.65%
Más Datos de OraSure Technologies Inc Compañía
OraSure Technologies, Inc. provides point-of-care and home diagnostic tests, sample management solutions, and microbiome laboratory and analytical services. The Company's product portfolio is divided into diagnostics products and sample management solutions. Its business consists of the development, manufacture, marketing and sale of diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Its diagnostic products include tests for diseases including COVID-19, HIV and Hepatitis C that are performed on a rapid basis at the point of care, and tests for drugs of abuse that are processed in a laboratory. Its business also includes molecular sample management solutions and services that are used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
Información de la empresa
Símbolo de cotizaciónOSUR
Nombre de la empresaOraSure Technologies Inc
Fecha de salida a bolsaNov 17, 1986
Director ejecutivoMs. Carrie Eglinton Manner
Número de empleados501
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 17
Dirección220 E First St
CiudadBETHLEHEM
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal18015
Teléfono15036416115
Sitio Webhttps://www.orasure.com/
Símbolo de cotizaciónOSUR
Fecha de salida a bolsaNov 17, 1986
Director ejecutivoMs. Carrie Eglinton Manner
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
460.99K
+24.25%
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
158.15K
+72.80%
Mr. John P. Kenny
Mr. John P. Kenny
Independent Director
Independent Director
147.20K
+4.74%
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
+93.09%
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+109.45%
Ms. Mara Glickman Aspinall
Ms. Mara Glickman Aspinall
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Robert W. Mcmahon
Mr. Robert W. Mcmahon
Independent Director
Independent Director
--
--
Mr. Jason Plagman
Mr. Jason Plagman
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Kenneth J. (Ken) Mcgrath
Mr. Kenneth J. (Ken) Mcgrath
Chief Financial Officer
Chief Financial Officer
460.99K
+24.25%
Dr. Nancy J. Gagliano, M.D.
Dr. Nancy J. Gagliano, M.D.
Independent Director
Independent Director
158.15K
+72.80%
Mr. John P. Kenny
Mr. John P. Kenny
Independent Director
Independent Director
147.20K
+4.74%
Mr. Lelio Marmora
Mr. Lelio Marmora
Independent Director
Independent Director
130.76K
+93.09%
Hon Dr. David J. Shulkin, M.D.
Hon Dr. David J. Shulkin, M.D.
Independent Director
Independent Director
126.33K
+109.45%
Ms. Mara Glickman Aspinall
Ms. Mara Glickman Aspinall
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Net product and services revenues - COVID-19
12.90M
43.10%
Net product and services revenues - HIV
9.11M
30.44%
Net product and service revenues -Molecular Products
4.33M
14.48%
Net product and services revenues - HCV
1.42M
4.74%
Other revenues - Other non Product revenues
934.00K
3.12%
Other
1.23M
4.12%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
20.34M
67.94%
Africa (Region)
7.19M
24.02%
Europe
1.64M
5.47%
Other Regions
770.00K
2.57%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Net product and services revenues - COVID-19
12.90M
43.10%
Net product and services revenues - HIV
9.11M
30.44%
Net product and service revenues -Molecular Products
4.33M
14.48%
Net product and services revenues - HCV
1.42M
4.74%
Other revenues - Other non Product revenues
934.00K
3.12%
Other
1.23M
4.12%
Estadísticas de accionistas
Actualizado: jue., 24 de jul
Actualizado: jue., 24 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
7.45%
Private Management Group, Inc.
7.30%
The Vanguard Group, Inc.
5.73%
Neuberger Berman, LLC
5.72%
Dimensional Fund Advisors, L.P.
5.11%
Other
68.68%
Accionistas
Accionistas
Proporción
BlackRock Institutional Trust Company, N.A.
7.45%
Private Management Group, Inc.
7.30%
The Vanguard Group, Inc.
5.73%
Neuberger Berman, LLC
5.72%
Dimensional Fund Advisors, L.P.
5.11%
Other
68.68%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
40.53%
Investment Advisor/Hedge Fund
30.98%
Hedge Fund
15.33%
Individual Investor
5.02%
Research Firm
2.45%
Pension Fund
0.48%
Bank and Trust
0.29%
Venture Capital
0.16%
Family Office
0.05%
Other
4.71%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
473
72.50M
96.93%
-16.88M
2025Q1
483
70.23M
93.78%
-12.52M
2024Q4
475
70.81M
94.94%
-10.37M
2024Q3
471
70.30M
94.28%
-10.80M
2024Q2
477
73.05M
98.74%
-8.54M
2024Q1
473
74.45M
97.36%
-5.59M
2023Q4
464
73.29M
99.74%
-5.62M
2023Q3
456
72.50M
98.73%
-4.51M
2023Q2
452
70.73M
96.51%
-2.77M
2023Q1
449
67.74M
89.31%
-3.74M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
BlackRock Institutional Trust Company, N.A.
5.58M
7.45%
+27.48K
+0.50%
Mar 31, 2025
Private Management Group, Inc.
4.42M
5.91%
+4.42M
--
Mar 31, 2025
The Vanguard Group, Inc.
4.29M
5.73%
+60.97K
+1.44%
Mar 31, 2025
Neuberger Berman, LLC
4.28M
5.72%
+653.02K
+18.00%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
3.82M
5.11%
-147.56K
-3.72%
Mar 31, 2025
Acadian Asset Management LLC
2.76M
3.68%
-144.45K
-4.98%
Mar 31, 2025
Renaissance Technologies LLC
2.57M
3.44%
-203.30K
-7.33%
Mar 31, 2025
American Century Investment Management, Inc.
2.51M
3.35%
+159.29K
+6.79%
Mar 31, 2025
Eglinton (Manner Carrie)
1.83M
2.45%
+142.46K
+8.44%
Jun 04, 2025
Geode Capital Management, L.L.C.
1.76M
2.35%
-87.12K
-4.72%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.47%
Vanguard US Value Factor ETF
0.07%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
0.07%
Lattice Hartford Multifactor Small Cap ETF
0.07%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
Avantis US Small Cap Value ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
WisdomTree US SmallCap Fund
0.03%
Principal U.S. Small-Cap ETF
0.02%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.47%
Vanguard US Value Factor ETF
Proporción0.07%
JPMorgan Diversified Return U.S. Small Cap Equity ETF
Proporción0.07%
Lattice Hartford Multifactor Small Cap ETF
Proporción0.07%
iShares Micro-Cap ETF
Proporción0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.04%
Avantis US Small Cap Value ETF
Proporción0.03%
Avantis US Small Cap Equity ETF
Proporción0.03%
WisdomTree US SmallCap Fund
Proporción0.03%
Principal U.S. Small-Cap ETF
Proporción0.02%
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI